KKR & Co. is reportedly considering selling its 53.8% controlling stake in Indian pharmaceutical company JB Chemicals & Pharmaceuticals Ltd. The US private equity firm is said to be exploring options and seeking financial advisers for a potential sale, with other buyout firms and industry players expressing preliminary interest. JB Pharma s shares have seen a 68% increase in the past year, valuing the company at just over $3 billion.
Britannia Industries Ltd.'s third quarter profit declined on account of a one-time gain in the base quarter but met analysts' estimates.
The consolidated net profit of the Marie Gold biscuit-maker fell 40.4% over the previous year to Rs 555.6 crore in the October-December quarter, according to an exchange filing on Wednesday. That compares with the Rs 552.8-crore consensus estimate of analysts tracked by Bloomberg.
JBCPs long term growth drivers remain intact led by 1) geographical expansion of legacy brands 2) improvement in MR productivity 3) scale-up in acquired portfolio 4) launch of new products & therapies 5) rise of contract manufacturing business and 6) improvement in FCF generation.
JB Chemicals & Pharmaceuticals Ltd, the Mumbai-based drugmaker majority-owned by private equity firm KKR, has acquired a portfolio of ophthalmology brands from Swiss giant Novartis ..
The board of directors at its meeting held on December 19, 2023 approved the execution of a trade mark licence agreement with Novartis Innovative Therapies AG, which is perpetual in nature for the Indian market, for a portfolio of select ophthalmology brands which will be effective in January 2027, JB Pharma said in a regulatory filing.